JPRN-UMIN000015193
招募中
1 期
Phase I of Vorinostat-Iressa combined therapy on resistance by BIM polymorphysim in EGFR Mutant Lung Cancer - VICTORY-J(Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer-JAPAN)
Cancer Research Center, Kanazawa University0 个研究点目标入组 18 人2014年9月17日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- on-small-cell lung cancer
- 发起方
- Cancer Research Center, Kanazawa University
- 入组人数
- 18
- 状态
- 招募中
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •Within 4 weeks after the final administration of a cytotoxic anticancer agent.Allowable enrollment when a 7\-day washout is completed after the final administration of an EGFR\-TKI. Surgery of a primary tumor or to the mediastinum must be completed at least 6 months before the onset of protocol treatment. Radiotherapy to the lungs considered necessary at the time of study entry or in the near future. Having an interstitial lung disease (including acute pulmonary disorder, interstitial pneumonia, and drug inducibility) or having a history thereof. Having radiation pneumonitis or having a history thereof. Having a large volume of or uncontrollable pleural effusion, ascites, or pericardial effusion Detection of known EGFR\-TKI resistance acquired by mutations of the genes, e.g., T790M. Suffering from a severe or poorly controlled systemic disease (e.g., unstable or decompensated respiratory disease, heart disease, renal disease, and liver disease)
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes - GFM-VOR-2007-1EUCTR2007-002212-26-FRGroupe Francophone des Myélodysplasies
已完成
1 期
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced SarcomaSarcomaNCT01879085Melissa Burgess, MD37
已完成
1 期
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent NeuroblastomaLocalized Unresectable NeuroblastomaRecurrent NeuroblastomaRegional NeuroblastomaStage 4 NeuroblastomaStage 4S NeuroblastomaNCT01208454National Cancer Institute (NCI)29
已完成
1 期
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00331955National Cancer Institute (NCI)40
进行中（未招募）
1 期
Vorinostat in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Relapsed Refractory Multiple MyelomaRelapsed myeloma.MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-005361-20-GBniversity of Leeds68